Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
12/2005
12/29/2005WO2004094599A3 Disease prevention and vaccination following thymic reactivation
12/29/2005WO2004084832A3 Measurement of estrogen activity in plants and a composition therefrom
12/29/2005WO2004082631A3 METHODS FOR PREPARATION AND USE OF 1α,24(S)-DIHYDROXYVITAMIN D2
12/29/2005WO2004073658A3 Isoflavone derivatives
12/29/2005WO2004069166A3 Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
12/29/2005WO2004062582A3 Combination therapy for anticoagulation
12/29/2005WO2004058191A3 Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
12/29/2005US20050288515 Chemical compounds
12/29/2005US20050288375 Method and composition for treating neurodegenerative disorders
12/29/2005US20050288364 Halogenated triptolide derivatives as immunomodulators and anticancer agents
12/29/2005US20050288316 Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists
12/29/2005US20050288315 4-((7-chloroquinolin-4-yl)aminoalkyleneamino-)-spiro(cyclohexane-1.5'-1H-4,5,6-trioxaindene )dicitrate; malaria; paraciticides; antiprotozoa agents; Plasmodium; synergistic; chloroquine-resistant; cost efficiency; industrial scale; penetration and activity of artemisine
12/29/2005US20050288293 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors
12/29/2005US20050288278 HIV replication inhibiting pyrimidines
12/29/2005US20050288276 Pharmaceutical formulation of olanzapine
12/29/2005US20050288218 Methods for treating and preventing sepsis using modified C1 inhibitor or fragments thereof
12/29/2005US20050287210 Also including 0.5-5 % polyvinylpyrrolidone and 5-40 % hydroxypropyl methylcellulose; administering an endothelial nitric oxide synthase agonist (an HMG-CoA reductase inhibitor) and a NO precursor (L-arginine hydrochloride) for cerebrovascular/cardiovascular disorders; anticholesterol agents
12/29/2005US20050287197 Method of treating insulin resistance, adult onset diabetes and metabolic syndrome x
12/29/2005US20050287152 Administering CTLA-4, tumor necrosis factor inhibitors, and immunogens
12/29/2005US20050287149 Human monoclonal antibodies against bacillus anthracis protective antigen
12/29/2005US20050287114 Water-soluble polymeric bone-targeting drug delivery system
12/29/2005DE20122504U1 Kristallines und reines Modafinil Crystalline and pure modafinil
12/28/2005EP1609781A1 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine
12/28/2005EP1609478A1 Exendin agonist peptide formulations
12/28/2005EP1608967A2 Compositions and methods for the diagnosis and treatment of tumor
12/28/2005EP1608962A2 Model for neurodegenerative disorders
12/28/2005EP1608767A2 Optimized expression of hpv 31 l1 in yeast
12/28/2005EP1608654A2 8-SUBSTITUTED-6, 7, 8,9-TETRAHY9DROPYRIMIDO (1,2- a) PYRIMIDIN-4-ONE DERIVATIVES
12/28/2005EP1608648A1 Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
12/28/2005EP1608628A2 Histone deacetylase inhibitors
12/28/2005EP1608627A2 Bicyclic anilide spirohydantoin cgrp receptor antagonists
12/28/2005EP1608622A2 Biaryl substituted 6-membered heterocyles as sodium channel blockers
12/28/2005EP1608407A2 Dispersible formulation of an anti-inflammatory agent
12/28/2005EP1608399A2 Ligands for tgf--beta binding proteins and uses thereof
12/28/2005EP1608380A2 Polymeric drug agents for the treatment of fibrotic disorders
12/28/2005EP1608359A2 Tumor-targeting drug-loaded particles
12/28/2005EP1608357A2 Treating or preventing hot flashes using prodrugs of gaba analogs
12/28/2005EP1608344A2 Oral formulations of cladribine
12/28/2005EP1608343A2 Cladribine formulations for improved oral and transmucosal delivery
12/28/2005EP1608342A2 Stable lamotrigine pharmaceutical compositions and processes for their preparation
12/28/2005EP1608320A2 Novel imidazoline receptor homologs
12/28/2005EP1608319A2 Improved inhibitors for the soluble epoxide hydrolase
12/28/2005EP1608318A2 Cxcr4 antagonists and methods of their use
12/28/2005EP1608317A2 Dipeptidyl peptidase inhibitors
12/28/2005EP1608316A2 Methods and compositions for treating and preventing inflammatory conditions
12/28/2005EP1608315A2 Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
12/28/2005EP1608314A2 Novel probiotic compositions and methods of using the same
12/28/2005EP1608313A2 Facially amphiphilic polymers and oligomers and uses thereof
12/28/2005EP1608312A2 Methods for obtaining colonization factors from bacterial strains
12/28/2005EP1608311A1 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy
12/28/2005EP1608308A2 Anti-inflammatory activity from lactic acid bacteria
12/28/2005EP1608306A2 Alkyl-substituted pcdf as a treatment for prostate cancer
12/28/2005EP1608289A2 Devices, methods, and compositions to prevent restenosis
12/28/2005EP1401502B1 Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
12/28/2005EP1303641B1 Method for recovery of copper from sulfidic ore materials using super-fine grinding and medium temperature pressure leaching
12/28/2005EP1066033B1 Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
12/28/2005EP1021204B1 Bioadhesive compositions and methods for topical administration of active agents
12/28/2005CN1714101A Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells.
12/28/2005CN1714077A 2-,3-4- or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy.
12/28/2005CN1713924A Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading
12/28/2005CN1713907A N-substituted pyrrolidin derivatives as dipeptidyl peptidase IV inhibitors
12/28/2005CN1713905A Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
12/28/2005CN1713891A Cosmetic and pharmaceutical foam
12/27/2005US6979726 Immunoconjugates
12/27/2005US6979679 Bone disorders; antiinflammatory agents; antiarthritic agents; mixture of chondroitin sulfate, n-acetylglucosamine and hyaluronic acid
12/22/2005WO2005121171A1 Proteins stabilizing hydrophobic molecules
12/22/2005WO2005120589A2 Contrast agent comprising alginate and an isotope or paramagnetic ion
12/22/2005WO2005120564A2 Vaccine compositions and methods
12/22/2005WO2005120437A2 Method for treating lupus
12/22/2005WO2005120436A2 Composition for treating post-surgical pain
12/22/2005WO2005120435A2 Method for preparing sustained release compositions and the use of said compositions for treating chronic diseases of central nervous system (cns)
12/22/2005WO2005058231A3 Rifamycin analogs and uses thereof
12/22/2005WO2005053610A3 Diamine and iminodiacetic acid hydroxamic acid derivatives
12/22/2005WO2005051321A3 Treatment of inflammatory bowel disease through induction of indoleamine 2,3-dioxygenase
12/22/2005WO2005051289A3 Homogeneous preparations of chimeric proteins
12/22/2005WO2005046621A3 Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
12/22/2005WO2005046600A3 Transdermal tulobuterol delivery
12/22/2005WO2005037235A3 Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
12/22/2005WO2005032466A3 Calcium phosphate-based materials containig zinc, magnesium, fluoride and carbonate
12/22/2005WO2005030125A3 Method of treating smallpox and monkeypox
12/22/2005WO2005027842A3 Combinations of drugs for the treatment of neoplasms
12/22/2005WO2005020892B1 Pharmaceutical compositions and methods for metabolic modulation
12/22/2005WO2005013912A3 Anti-fcrn antibodies for treatment of auto/allo immune conditions
12/22/2005WO2005000216A8 Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
12/22/2005WO2004098512A3 Malonamides and malonamide derivatives as modulators of chemokine receptor activity
12/22/2005WO2004093823A3 Polyethelene glycol link glp-1 compounds
12/22/2005WO2004082621A3 Novel ppar agonists, pharmaceutical compositions and uses thereof
12/22/2005WO2004060317A3 Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia
12/22/2005WO2004058159A3 Branched immunomodulatory compounds and methods of using the same
12/22/2005WO2004041160A3 Methods and animal model for analyzing age-related macular degeneration
12/22/2005US20050282901 Compounds and methods for delivery of prostacyclin analogs
12/22/2005US20050282869 Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess therewith
12/22/2005US20050282817 4-(3-Phenyl-3-carbocycloylpropyl)-1-phenyl- or pyridylpiperazine derivatives: 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)propyl]piperazine oxalate; serotonin receptor antagonists; obesity
12/22/2005US20050282809 Heteroaryl-hydrazone compounds
12/22/2005US20050282232 Screening for modulators of subcellular location of c-Rel protein in cells; identifying modulators of autoimmune/inflammatory disorders
12/22/2005US20050282154 Angiotensin-converting enzyme-2 as a receptor for the SARS coronavirus
12/22/2005US20050281903 Extract of Stephaniae sinica Diels and methods of using the same
12/22/2005US20050281902 Compositions containing an active fraction isolated from Lycium barbarum and methods of using the same
12/22/2005US20050281894 Administering extract from the shells of two-horned and four-horned fruits of Trapa natans L. inhibiting metastasis of cancer
12/22/2005US20050281867 Nitric oxide inducing agents
1 ... 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 ... 295